232 related articles for article (PubMed ID: 38172189)
1. PRMT5 inhibition shows in vitro efficacy against H3K27M-altered diffuse midline glioma, but does not extend survival in vivo.
Brown EJ; Balaguer-Lluna L; Cribbs AP; Philpott M; Campo L; Browne M; Wong JF; Oppermann U; Carcaboso ÁM; Bullock AN; Farnie G
Sci Rep; 2024 Jan; 14(1):328. PubMed ID: 38172189
[TBL] [Abstract][Full Text] [Related]
2. STAT3 is a biologically relevant therapeutic target in H3K27M-mutant diffuse midline glioma.
Zhang L; Nesvick CL; Day CA; Choi J; Lu VM; Peterson T; Power EA; Anderson JB; Hamdan FH; Decker PA; Simons R; Welby JP; Siada R; Ge J; Kaptzan T; Johnsen SA; Hinchcliffe EH; Daniels DJ
Neuro Oncol; 2022 Oct; 24(10):1700-1711. PubMed ID: 35397475
[TBL] [Abstract][Full Text] [Related]
3. Real-time drug testing of paediatric diffuse midline glioma to support clinical decision making: The Zurich DIPG/DMG centre experience.
Mueller T; Laternser S; Guerreiro Stücklin AS; Gerber NU; Mourabit S; Rizo M; Rushing EJ; Kottke R; Grotzer M; Krayenbühl N; Nazarian J; Mueller S
Eur J Cancer; 2023 Jan; 178():171-179. PubMed ID: 36455411
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic strategies for diffuse midline glioma from high-throughput combination drug screening.
Lin GL; Wilson KM; Ceribelli M; Stanton BZ; Woo PJ; Kreimer S; Qin EY; Zhang X; Lennon J; Nagaraja S; Morris PJ; Quezada M; Gillespie SM; Duveau DY; Michalowski AM; Shinn P; Guha R; Ferrer M; Klumpp-Thomas C; Michael S; McKnight C; Minhas P; Itkin Z; Raabe EH; Chen L; Ghanem R; Geraghty AC; Ni L; Andreasson KI; Vitanza NA; Warren KE; Thomas CJ; Monje M
Sci Transl Med; 2019 Nov; 11(519):. PubMed ID: 31748226
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic avenues for targeting treatment challenges of diffuse midline gliomas.
Noon A; Galban S
Neoplasia; 2023 Jun; 40():100899. PubMed ID: 37030112
[TBL] [Abstract][Full Text] [Related]
6. Targeted therapy with anlotinib for a H3K27M mutation diffuse midline glioma patient with PDGFR-α mutation: a case report.
Wang Q; Niu W; Pan H
Acta Neurochir (Wien); 2022 Aug; 164(8):2063-2066. PubMed ID: 34812950
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic targeting of prenatal pontine ID1 signaling in diffuse midline glioma.
Messinger D; Harris MK; Cummings JR; Thomas C; Yang T; Sweha SR; Woo R; Siddaway R; Burkert M; Stallard S; Qin T; Mullan B; Siada R; Ravindran R; Niculcea M; Dowling AR; Bradin J; Ginn KF; Gener MAH; Dorris K; Vitanza NA; Schmidt SV; Spitzer J; Li J; Filbin MG; Cao X; Castro MG; Lowenstein PR; Mody R; Chinnaiyan A; Desprez PY; McAllister S; Dun MD; Hawkins C; Waszak SM; Venneti S; Koschmann C; Yadav VN
Neuro Oncol; 2023 Jan; 25(1):54-67. PubMed ID: 35605606
[TBL] [Abstract][Full Text] [Related]
8. The intrinsic and microenvironmental features of diffuse midline glioma: Implications for the development of effective immunotherapeutic treatment strategies.
Persson ML; Douglas AM; Alvaro F; Faridi P; Larsen MR; Alonso MM; Vitanza NA; Dun MD
Neuro Oncol; 2022 Sep; 24(9):1408-1422. PubMed ID: 35481923
[TBL] [Abstract][Full Text] [Related]
9. Dual IGF1R/IR inhibitors in combination with GD2-CAR T-cells display a potent anti-tumor activity in diffuse midline glioma H3K27M-mutant.
de Billy E; Pellegrino M; Orlando D; Pericoli G; Ferretti R; Businaro P; Ajmone-Cat MA; Rossi S; Petrilli LL; Maestro N; Diomedi-Camassei F; Pezzullo M; De Stefanis C; Bencivenga P; Palma A; Rota R; Del Bufalo F; Massimi L; Weber G; Jones C; Carai A; Caruso S; De Angelis B; Caruana I; Quintarelli C; Mastronuzzi A; Locatelli F; Vinci M
Neuro Oncol; 2022 Jul; 24(7):1150-1163. PubMed ID: 34964902
[TBL] [Abstract][Full Text] [Related]
10. Optimal therapeutic targeting by HDAC inhibition in biopsy-derived treatment-naïve diffuse midline glioma models.
Vitanza NA; Biery MC; Myers C; Ferguson E; Zheng Y; Girard EJ; Przystal JM; Park G; Noll A; Pakiam F; Winter CA; Morris SM; Sarthy J; Cole BL; Leary SES; Crane C; Lieberman NAP; Mueller S; Nazarian J; Gottardo R; Brusniak MY; Mhyre AJ; Olson JM
Neuro Oncol; 2021 Mar; 23(3):376-386. PubMed ID: 33130903
[TBL] [Abstract][Full Text] [Related]
11. A comprehensive genomic study of 390 H3F3A-mutant pediatric and adult diffuse high-grade gliomas, CNS WHO grade 4.
Williams EA; Brastianos PK; Wakimoto H; Zolal A; Filbin MG; Cahill DP; Santagata S; Juratli TA
Acta Neuropathol; 2023 Sep; 146(3):515-525. PubMed ID: 37524847
[TBL] [Abstract][Full Text] [Related]
12. [Diffuse midline glioma].
Saito R
No Shinkei Geka; 2022 Jan; 50(1):29-38. PubMed ID: 35169084
[TBL] [Abstract][Full Text] [Related]
13. Epigenetic-Targeted Treatments for H3K27M-Mutant Midline Gliomas.
Lu VM; Daniels DJ
Adv Exp Med Biol; 2021; 1283():73-84. PubMed ID: 33155139
[TBL] [Abstract][Full Text] [Related]
14. Transcriptomic and epigenetic profiling of 'diffuse midline gliomas, H3 K27M-mutant' discriminate two subgroups based on the type of histone H3 mutated and not supratentorial or infratentorial location.
Castel D; Philippe C; Kergrohen T; Sill M; Merlevede J; Barret E; Puget S; Sainte-Rose C; Kramm CM; Jones C; Varlet P; Pfister SM; Grill J; Jones DTW; Debily MA
Acta Neuropathol Commun; 2018 Nov; 6(1):117. PubMed ID: 30396367
[TBL] [Abstract][Full Text] [Related]
15. NTRK Fusions Can Co-Occur With H3K27M Mutations and May Define Druggable Subclones Within Diffuse Midline Gliomas.
Dahl NA; Donson AM; Sanford B; Wang D; Walker FM; Gilani A; Foreman NK; Tinkle CL; Baker SJ; Hoffman LM; Venkataraman S; Vibhakar R
J Neuropathol Exp Neurol; 2021 Mar; 80(4):345-353. PubMed ID: 33749791
[TBL] [Abstract][Full Text] [Related]
16. Prognostic Indicators for H3K27M-Mutant Diffuse Midline Glioma: A Population-Based Retrospective Surveillance, Epidemiology, and End Results Database Analysis.
Adhikari S; Bhutada AS; Ladner L; Cuoco JA; Entwistle JJ; Marvin EA; Rogers CM
World Neurosurg; 2023 Oct; 178():e113-e121. PubMed ID: 37423332
[TBL] [Abstract][Full Text] [Related]
17. Advanced MR imaging and
Piccardo A; Tortora D; Mascelli S; Severino M; Piatelli G; Consales A; Pescetto M; Biassoni V; Schiavello E; Massollo M; Verrico A; Milanaccio C; Garrè ML; Rossi A; Morana G
Eur J Nucl Med Mol Imaging; 2019 Jul; 46(8):1685-1694. PubMed ID: 31030232
[TBL] [Abstract][Full Text] [Related]
18. An EZH2 blocker sensitizes histone mutated diffuse midline glioma to cholesterol metabolism inhibitors through an off-target effect.
Rahal F; Capdevielle C; Rousseau B; Izotte J; Dupuy JW; Cappellen D; Chotard G; Ménard M; Charpentier J; Jecko V; Caumont C; Gimbert E; Grosset CF; Hagedorn M
Neurooncol Adv; 2022; 4(1):vdac018. PubMed ID: 35300150
[TBL] [Abstract][Full Text] [Related]
19. Diffuse midline glioma: review of epigenetics.
Cooney TM; Lubanszky E; Prasad R; Hawkins C; Mueller S
J Neurooncol; 2020 Oct; 150(1):27-34. PubMed ID: 32804378
[TBL] [Abstract][Full Text] [Related]
20. Current knowledge on the immune microenvironment and emerging immunotherapies in diffuse midline glioma.
Price G; Bouras A; Hambardzumyan D; Hadjipanayis CG
EBioMedicine; 2021 Jul; 69():103453. PubMed ID: 34157482
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
